Citations

Clear

9383 citation(s) found for "Thomas, PS".

Polo-Like Kinase 1 Is Essential for Early Embryonic Development and Tumor Suppression
Lu, Lin-Yu, Wood, Jamie L., Minter‐Dykhouse, Katherine, Saunders, Thomas L. , Yu, Xiaochun , Lu, Lin‐Yu , Ye, Lin , Chen, Junjie

Mayo Clinic

Molecular and Cellular Biology | September 16, 2008 | Volume: 28 | Issue: 22 | Pages: 6870-6876

10.1128/mcb.00392-08 | PMID 18794363 Get It

WOUND-HEALING PROPERTIES OF TRANSFORMING GROWTH FACTOR β (TGF-β) INDUCIBLE EARLY GENE 1 (TIEG1) KNOCKOUT MICE
Taguchi, Manabu, Moran, Steven L. , Zobitz, Mark E., Zhao, Chunfeng , Subramaniam, Malayannan , Spelsberg, Thomas C., Amadio, Peter C.

Mayo Clinic

Journal of Musculoskeletal Research | September 15, 2008 | Volume: 11 | Issue: 02 | Pages: 63-69

10.1142/s0218957708002012 | PMID 20016760 Get It

Transforming growth factor beta (TGF-β) has a broad effect on wound healing, but many questions remain about the regulation of TGF-β during the healing process. TGF-β inducible early gene 1 (TIEG1) is a primary response gene for TGF-β that controls the activities of the TGF-β/Smad pathway, the primary TGF-β signaling pathway. The purpose of this study was to investigate the role of TIEG1 in cutaneous wound healing using TIEG1 knockout mice. The wound healing in TIEG1 knockout mice and wild-type controls was evaluated by wound breaking strength, Western blot, and histology at postoperative days 3, 7, and 14. Although re-epithelialization of both groups was similarly complete at day 7, the TIEG1 knockout mice had a significantly lower wound breaking strength than the controls at postoperative day 14. These results suggest that TIEG1 expression may be an important factor involved in the initiation and support of normal cutaneous wound healing.
Association of Soluble Cell Adhesion Molecules with Ankle-Brachial Index in a Biethnic Cohort of Predominantly Hypertensive Individuals
Khaleghi, Mahyar, Ali, Zeenat, Mosley, Thomas H. , Turner, Stephen T. , Kullo, Iftikhar J.

Mayo Clinic

Clinical Chemistry | September 11, 2008 | Volume: 54 | Issue: 11 | Pages: 1788-1795

10.1373/clinchem.2008.107003 | PMID 18787016 Get It

Abstract Background: Higher plasma concentrations of soluble adhesion molecules have been shown to be associated with increased risk of cardiovascular events. We investigated the association of soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) with ankle-brachial index (ABI), a measure of peripheral arterial disease (PAD), in a biethnic cohort of adults without known coronary heart disease or stroke. Methods: Participants included 1102 blacks (mean age, 63 years; 74% women) and 1013 non-Hispanic whites (mean age, 58 years; 59% women) belonging to sibships ascertained on the basis of hypertension. We measured plasma concentrations of sICAM-1 and sVCAM-1 using high-sensitivity immunoassays and ABI using a standard protocol; PAD was defined as ABI <0.9. We used generalized estimating equations to assess whether sICAM-1 and sVCAM-1 were associated with ABI and PAD, independently of conventional risk factors. Results: After adjustment for conventional risk factors, blacks with sICAM-1 and sVCAM-1 concentrations in the highest quartiles had lower ABIs than those in the lowest quartiles (mean ABI 1.02 vs 0.98, P = 0.007, vs 1.02 vs 0.99, P = 0.003, respectively). In multivariable logistic regression analysis, sICAM-1 and sVCAM-1 concentrations in the highest quartiles were each associated with a higher odds ratio of having PAD, compared with the lowest quartiles: odds ratio (95% CI): 5.2 (1.8–15.2) and 2.2 (1.0–4.8), respectively. In contrast, in non-Hispanic whites, sICAM-1 and sVCAM-1 concentrations were not associated with ABI or PAD. Conclusions: Higher sICAM-1 and sVCAM-1 concentrations were independently associated with lower ABI and PAD in blacks, but not in non-Hispanic whites.
The C ombined Approach to L ysis Utilizing E ptifibatide a nd r t-PA in Acute Ischemic Stroke
Pancioli, Arthur , Brott, Thomas G. , Tomsick, Thomas A. , Bean, Judy A., Zoppo, Gregory del, Kleindorfer, Dawn , Woo, Daniel , Khatri, Pooja , Castaldo, John , Frey, James L., Gebel, James, Kidwell, Chelsea S., Kwiatkowski, Thomas , Libman, Richard , Mackenzie, Richard S., Starkman, Sidney , Thurman, R. Jason, Jauch, Edward C. , Liebeskind, David S. , Meurer, William J. , Buck, Brian , Broderick, Joseph P. , Khoury, Jane , Kasner, Scott Eric , Scott, Phillip , Liebeskind, David S. , Buck, Brian H , Khatri, Pooja

Mayo Clinic

Stroke | September 5, 2008 | Volume: 39 | Issue: 12 | Pages: 3268-3276

10.1161/strokeaha.108.517656 | PMID 18772447 Get It

Background and Purpose— Multiple approaches are being studied to enhance the rate of thrombolysis for acute ischemic stroke. Treatment of myocardial infarction with a combination of a reduced-dose fibrinolytic agent and a glycoprotein (GP) IIb/IIIa receptor antagonist has been shown to improve the rate of recanalization versus fibrinolysis alone. The c ombined approach to l ysis utilizing e ptifibatide a nd r ecombinant tissue-type plasminogen activator (rt-PA) (CLEAR) stroke trial assessed the safety of treating acute ischemic stroke patients within 3 hours of symptom onset with this combination. Methods— The CLEAR trial was a National Institutes of Health/National Institute of Neurological Disorders and Stroke–funded multicenter, double-blind, randomized, dose-escalation and safety study. Patients were randomized 3:1 to either low-dose rt-PA (tier 1=0.3 mg/kg, tier 2=0.45 mg/kg) plus eptifibatide (75 μg/kg bolus followed by 0.75 μg/kg per min infusion for 2 hours) or standard-dose rt-PA (0.9 mg/kg). The primary safety end point was the incidence of symptomatic intracerebral hemorrhage within 36 hours. Secondary analyses were performed regarding clinical efficacy. Results— Ninety-four patients (40 in tier 1 and 54 in tier 2) were enrolled. The combination group of the 2 dose tiers (n=69) had a median age of 71 years and a median baseline National Institutes of Health Stroke Scale (NIHSS) score of 14, and the standard-dose rt-PA group (n=25) had a median age of 61 years and a median baseline NIHSS score of 10 ( P =0.01 for NIHSS score). Fifty-two (75%) of the combination treatment group and 24 (96%) of the standard treatment group had a baseline modified Rankin scale score of 0 ( P =0.04). There was 1 (1.4%; 95% CI, 0% to 4.3%) symptomatic intracranial hemorrhage in the combination group and 2 (8.0%; 95% CI, 0% to 19.2%) in the rt-PA–only arm ( P =0.17). During randomization in tier 2, a review by the independent data safety monitoring board demonstrated that the safety profile of combination therapy at the tier 2 doses was such that further enrollment was statistically unlikely to indicate inadequate safety for the combination treatment group, the ultimate outcome of the study. Thus, the study was halted. There was a trend toward increased clinical efficacy of standard-dose rt-PA compared with the combination treatment group. Conclusions— The safety of the combination of reduced-dose rt-PA plus eptifibatide justifies further dose-ranging trials in acute ischemic stroke.
Cat‐scratch disease of the head and neck in a pediatric population: Surgical indications and outcomes
Munson, Patrick D., Boyce, Thomas G. , Salomão, Diva R. , Orvidas, Laura J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | August 23, 2008 | Volume: 139 | Issue: 3 | Pages: 358-363

10.1016/j.otohns.2008.06.030 | PMID 18722212 Get It

ObjectiveTo identify the presentation of pediatric patients with head and neck manifestations of cat‐scratch disease, one of the most common causes of subacute or chronic lymphadenitis in children, and to determine surgical indications and outcomes.Study DesignCase series.Subjects and MethodsAll pediatric patients from infancy to age 19 years who presented with clinical symptoms of cat‐scratch disease and had an IgG serological test result of more than 1:128 for Bartonella henselae.ResultsNine patients had cat‐scratch disease of the head and neck. Median age at presentation was 4 years; median time from symptom onset to presentation was 20 days. Six (67%) children underwent surgical procedures, and median time from presentation to surgical procedure was 43 days.ConclusionDespite conservative treatment, a minority of pediatric patients with cat‐scratch disease may require surgical drainage of abscess and removal of lymph nodes. Surgical treatment provides tissue for diagnosis, is generally well tolerated, affords improved recovery, and has minimal complications. © 2008 American Academy of Otolaryngology‐Head and Neck Surgery Foundation. All rights reserved.
Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial
Hertzberg, Vicki , Ingall, Timothy J., O’Fallon, W. Michael, Asplund, Kjell , Louis, Thomas A. , Christianson, Teresa J., Goldfrank, Lewis R.

Mayo Clinic

Clinical Trials | August 12, 2008 | Volume: 5 | Issue: 4 | Pages: 308-315

10.1177/1740774508094404 | PMID 18697845 Get It

Background Treatment group imbalances in baseline stroke severity in the NINDS intravenous t-PA for acute stroke treatment trial led to controversy regarding the efficacy of tissue plasminogen activator (t-PA) in the treatment of acute ischemic stroke. Purpose Describe the steps used to independently re-evaluate this trial. Methods NIH appointed an independent multidisciplinary committee that gained access to the original data. We undertook analyses of t-PA efficacy accounting for this imbalance, as well as analyses to identify subgroups that experienced additional harm or benefit from t-PA. Analyses of time from stroke onset to treatment (OTT), blood pressure, and intracerebral hemorrhage are given as illustrations. Results Despite subgroup imbalances in baseline stroke severity, when t-PA was administered to acute ischemic stroke patients according to study protocol, there was a statistically significant and clinically important benefit of t-PA treatment resulting in a higher likelihood of having a favorable clinical outcome at 3 months. Moreover, we were unable to identify subgroups of patients between which t-PA treatment effect differed, albeit these analyses had low power. These data failed to support the NINDS investigators' conclusion that effect of t-PA therapy diminished with increasing values of OTT within the protocol-specified 3 h time limit. In addition, the blood pressure measurements were highly variable and inconsistently determined so as to be too unreliable for inclusion in analysis. Conclusion With new NIH requirements for data-sharing, the frequency of re-analysis of clinical trial data may increase substantially. This re-evaluation provides a blueprint for future re-evaluations of other trials. These best practices include re-analysis of the study data, after suitable replication, by an independent multidisciplinary committee, including a skilled statistical programmer analyst. Primary investigators should address significant errors determined in such re-analyses. Clinical Trials 2008; 5: 308—315. http://ctj.sagepub.com
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
Lee, Stephanie J. , Kukreja, Manisha, Szer, Jeff , Arora, Mukta , Woolfrey, Ann E. , Cervantes, Francisco , Halter, Joerg , Marks, David I. , Olavarría, Eduardo, Stadtmauer, Edward A. , Abecasis, Manuel, Gupta, Vikas , Khoury, H. Jean, Hale, Gregory A., Rizzieri, David A. , Antin, Joseph H. , Bolwell, Brian J., Carabasi, Matthew, Copelan, Edward A. , İlhan, Osman , Litzow, Mark R. , Schouten, H, Zander, Axel R., Horowitz, Mary M. , Halter, Jörg , Wang, Tao , Giralt, Sergio , Champlin, Richard E. , Gale, Robert Peter , Keating, Armand , McCarthy, Philip L. , George, Biju , Liesveld, Jane L. , Maziarz, Richard Thomas , Gupta, Vikas , Lee, Stephanie J

Mayo Clinic

Blood | July 30, 2008 | Volume: 112 | Issue: 8 | Pages: 3500-3507

10.1182/blood-2008-02-141689 | PMID 18664621 Get It

AbstractImatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM+) and 900 subjects who did not receive IM before HCT (IM−) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival. Acute graft-versus-host disease rates were similar between IM+ and IM− groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.
Outcomes of Laparoscopic Radical Nephrectomy in the Setting of Vena Caval and Renal Vein Thrombus: Seven-Year Experience
Martin, George L., Castle, Erik P., Martin, Aaron D. , Desai, Premal J., Lallas, Costas D. , Ferrigni, Robert G., Andrews, Paul E.

Mayo Clinic

Journal of Endourology | July 25, 2008 | Volume: 22 | Issue: 8 | Pages: 1681-1686

10.1089/end.2008.0035 | PMID 18657033 Get It

Stroke Genetic Research and Adults With Impaired Decision-Making Capacity
Chen, Donna T. , Brott, Thomas G. , Brown, Robert D., Worrall, Bradford B. , Meschia, James F.

Mayo Clinic

Stroke | July 25, 2008 | Volume: 39 | Issue: 10 | Pages: 2732-2735

10.1161/strokeaha.108.515130 | PMID 18658034 Get It

Background and Purpose— In stroke and other brain disorders, severely affected phenotypes often impair decision-making capacity. Severity is in part under genomic control. Therefore, scientifically valid research into genetic risk may require inclusion of such impaired individuals. U.S. Federal regulations do not detail rules governing enrollment of adults with impaired decision-making capacity into genetic research. Rather, policy and practice are locally determined. This study was conducted to obtain data on how investigators and IRBs handle surrogate authorization to enroll probands into a genetic study where some may lack capacity because of ischemic stroke. Methods— Sequential surveys of sites from an ongoing North American study investigating genetic risks for ischemic stroke (2003: 49 sites, response rate=100%; 2007: 53 sites; response rate=91%) assessed whether and how investigators enroll adults with impaired decision-making capacity and determined frequency of IRB approval for enrollment by surrogate authorization. Results— Approximately 40% of sites report that their IRBs do not approve surrogate authorization to enroll stroke patients—43% (21/49) in 2003 and 35% (17/48) in 2007. Thirty-three percent of sites report evaluating eligible adults who lacked capacity to provide their own informed consent; 18% (9/49) in 2003 and 15% (7/48) in 2007 have enrolled these individuals. Surrogate enrollment is the most common method used. Most sites have not enrolled any individual lacking capacity to give his or her own consent. Conclusions— Our study suggests that enrollment by surrogate authorization into stroke genetic research is often not approved by IRBs, and even when allowed is frequently not used. For disorders like stroke, this situation has significant implications for scientific validity.